Les Dorfman

Publication Details

  • PHASE-1 CLINICAL-TRIAL OF CHIMERIC MONOCLONAL ANTI-CD4 ANTIBODY IN MULTIPLE-SCLEROSIS Lindsey, J. W., Hodgkinson, S., Mehta, R., Siegel, R. C., Mitchell, D. J., Lim, M., Piercy, C., Tram, T., Dorfman, L., ENZMANN, D., Steinman, L. LIPPINCOTT WILLIAMS & WILKINS. 1994: 413-419


    We conducted an open trial of cM-T412, a chimeric monoclonal anti-CD4 antibody, in 29 patients with MS. This antibody caused a prompt and long-lasting depletion of circulating CD4 (helper/inducer) lymphocytes. The mean (+/- SE) CD4 count for the group decreased from 870 (+/- 66) cells/mm3 at baseline to 76 (+/- 11) 3 hours after treatment, and then increased to 425 (+/- 38) at 1 month after treatment and 475 (+/- 39) at 6 months after treatment. Numbers of CD8 (cytotoxic/suppressor) lymphocytes, B lymphocytes, granulocytes, and monocytes changed transiently but showed no significant long-term effects. The most common side effects were headache, nausea, myalgia, fever, and tachycardia occurring in the first few hours after treatment. No serious or unexpected infections or other significant adverse effects occurred. Kurtzke EDSS scores remained stable, and MRI scans showed less contrast enhancement 1 week after treatment. We conclude that treatment of MS patients with cM-T412 chimeric anti-CD4 antibody is well tolerated at the doses tested and produces a long-lasting, selective depletion of CD4 lymphocytes.

    View details for Web of Science ID A1994NB93400008

    View details for PubMedID 8145907

Stanford Medicine Resources:

Footer Links: